As PFAS health effects are increasingly recognized and EPA regulations raise public awareness of contamination, healthcare providers are encountering patients who are concerned about their PFAS exposure or presenting with health conditions potentially linked to PFAS. Understanding available exposure assessment tools, when to order PFAS serum testing, and how to counsel patients about exposure reduction enables providers to address these concerns effectively and evidence-based.
Exposure History Assessment
The first step in PFAS exposure assessment is a focused environmental and occupational history. Key questions for patients concerned about PFAS include:
- What is the source of home drinking water (municipal utility or private well)? Has it been tested for PFAS?
- What is the patient’s occupation? Current or past employment in firefighting, military, semiconductor manufacturing, fluorochemical production, or PFAS-using industries represents elevated exposure risk
- Has the patient lived near military bases, airports, PFAS manufacturing facilities, or landfills?
- What is the patient’s typical diet? Frequent consumption of local fish from potentially contaminated waters; frequent consumption of microwave popcorn, fast food, or other foods in PFAS-treated packaging; and consumption of local produce from potentially contaminated farms all represent elevated dietary exposure routes
- What is the patient’s history of consuming commercially bottled water versus tap water?
PFAS Serum Testing: Indications and Limitations
PFAS serum testing is available through commercial laboratories and provides direct measurement of body burden. Indications for PFAS serum testing include:
- Patient living in an area with documented public water PFAS contamination above MCLs
- Patient with private well water testing showing elevated PFAS
- Occupational exposure concern (firefighter, military, industrial PFAS worker)
- Patient with unexplained thyroid dysfunction, elevated cholesterol, immune-related conditions, or other PFAS-associated health effects who has plausible exposure history
- Patient seeking baseline assessment before or after implementing exposure reduction measures
Limitations: Serum testing requires specialized laboratory analysis (not all commercial labs offer PFAS testing); cost ranges from $200–500+ for comprehensive panels; results must be interpreted in the context of exposure history and population reference ranges; and serum levels reflect integrated past exposure, not just current intake.
Interpreting Serum PFAS Results
Reference ranges for PFAS serum levels are derived from NHANES population surveys. Current median PFAS levels in the US general adult population (2017–2018 NHANES data):
- PFOS: ~3.0 ng/mL median; 95th percentile ~10 ng/mL
- PFOA: ~1.9 ng/mL median; 95th percentile ~5.5 ng/mL
- PFHxS: ~1.4 ng/mL median; 95th percentile ~4.8 ng/mL
Patients with levels substantially above these population medians have higher-than-average PFAS body burden, though “safe” levels have not been definitively established for individual clinical interpretation.
Patient Counseling on PFAS Exposure Reduction
Evidence-based counseling for PFAS-exposed patients should prioritize:
- Water filtration: Install NSF/ANSI 58 certified RO system for drinking and cooking water — the most impactful single intervention for most patients
- Dietary modifications: Reduce consumption of PFAS-treated food packaging (microwave popcorn, fast food wrappers); increase consumption of fresh, whole foods; follow any local fish consumption advisories
- Consumer product choices: Transition away from PFAS-treated cookware, stain-resistant carpeting, and PFAS-containing personal care products
- Occupational exposure control: For occupationally exposed workers, discuss exposure controls and personal protective equipment with their occupational health provider
Emphasize that body burden will decline gradually after exposure reduction — long half-lives mean this is a months-to-years process, and patients should not expect immediate serum level changes. Follow-up serum testing 1–2 years after implementing comprehensive exposure reduction documents progress and maintains patient engagement with protective behaviors.